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OBJECTIVES:  A prospective cohort study was conducted 
among human immunodefi  ciency virus (HIV) infected in-
patients with tuberculosis (TB) or other opportunistic 
infections (OIs) in South Africa to estimate subsequent 
antiretroviral therapy (ART) uptake and survival.
METHODS:  Logistic regression modeling explored associ-
ations between baseline characteristics and starting ART, 
and ART exposure-adjusted incidence of death was esti-
mated over 6 months of follow-up.
RESULTS:  Among 49 participants enrolled, median CD4 
cell count at hospital discharge was 42 cells/μl and the 
most common presenting OIs were TB (76%), Pneumo-
cystis pneumonia (8%), chronic diarrhea (8%), crypto-
coccal meningitis (6%), and Toxoplasma gondii (4%). 
By 6 months, only 20 (45%) patients had initiated ART, 
and four (8%) were lost to follow-up. ART uptake was in-
dependently associated with previous use of traditional 
medicine (OR 7.2, 95%CI 1.4–55.1) and with less ad-
vanced HIV infection (baseline CD4 count per 50 cells/
μl increase OR 1.4, 95%CI 0.9–2.2). A total of 14 
(31%) patients died before initiating ART; the monthly 
incidence of death did not decrease over the 6-month 
interval. 
CONCLUSION: The high mortality observed within the 
6 months following hospitalization with TB or other acute 
OIs indicate that mechanisms are needed to expedite 
ART for patients after an acquired immune-defi  ciency 
syndrome defi  ning illness.
KEY WORDS:  co-infection; tuberculosis; antiretroviral 
therapy 
SIGNIFICANT pre-antiretroviral therapy (ART) mor-
tality has been documented among human immuno-
defi  ciency virus (HIV) infected out-patients awaiting 
initiation of ART in resource-limited settings.1,2 In 
South Africa, the delay of ART until completion of 
tuberculosis (TB) therapy was associated with an in-
creased risk of death among ART-eligible patients.3 A 
growing evidence base suggests that patients with re-
cent opportunistic infection (OI) may benefi  t from 
rapid ART initiation.4 However, following discharge 
from hospital, HIV-infected patients with recent OI 
and patients in resource-limited settings face several 
potential barriers to timely initiation of ART, poten-
tially placing them at increased risk for poor outcome. 
These barriers include the loss of functional capacity 
associated with hospitalization, as well as structural 
hurdles such as pre-ART readiness-assessment pro-
cesses. A signifi  cant delay in initiating ART would be 
expected to adversely impact survival, estimated to 
be only 1.3 years after an acquired immune-defi  ciency 
syndrome (AIDS) defi  ning illness.5
To improve ART uptake and reduce pre-ART mor-
tality among ART-eligible in-patients with TB or 
other OI, a pilot program was initiated at McCord 
Hospital in Durban, South Africa, to expedite access 
to ART after hospitalization. In the pilot program, 
HIV-infected patients with TB or other OI transi-
tioned rapidly from the in-patient ward to a step-
down center for initiation of ART. Eligible patients 
who did not enter this pilot program and instead 
sought ART as out-patients were also prospectively 
followed, and their outcomes are presented here.
METHODS
McCord Hospital is a 166-bed general hospital in 
South Africa that provides in-patient care to patients 
from Durban townships. HIV-infected patients with 
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of cotrimoxazole, date of HIV diagnosis (concurrent 
with current OI vs. prior), BMI, presence of thrush, 
TB (vs. other OI), CD4 cell count, percentage of lym-
phocytes, ALT, hemoglobin, creatinine and albumin. 
All covariates were initially fi  t alone (univariate mod-
els), and only those suggestive of an association were 
fi  t in a multivariable model. Logistic regression anal-
yses were performed using SAS software, version 9.1 
(SAS Institute, Cary, NC, USA). All tests of statistical 
signifi   cance were 2-sided, without adjustment for 
multiple testing. 
Summaries of survival used ART exposure strati-
fi   ed and interval-specifi   c incidence rate estimation. 
Both the incidence point estimate and a 95% confi  -
dence interval (CI) on the estimate are presented. To 
estimate survival by ART exposure, if and when in-
dividuals started ART, their subsequent follow-up 
survival time contributed to the post-ART initiation 
stratum. Incidence estimation was performed using 
STATA  software, version 8.2 (Stata Corp, College 
Station, TX, USA).
Ethical approval
The study was approved by the McCord Hospital 
Research Ethics Committee in Durban, South Africa.
RESULTS
Forty-nine patients with HIV and TB or other acute 
OI requiring hospitalization were prospectively en-
rolled between December 2006 and February 2007 
(Figure 1). The reasons cited for declining participa-
tion in the immediate ART program were cost of hos-
pitalization (74%), family or employment obligations 
(19%) or other (7%). 
Baseline characteristics at admission 
with tuberculosis or other acute OI
At admission, the median age was 34 (IQR 28–40), 
49% were female and the median CD4 cell count 
was 42 cells/μl (IQR 14–106; Table 1). The me-
dian time since initial HIV diagnosis was 2.9 months 
(IQR 1.1–3.9) and, for 67% of patients, the current 
admission was the fi  rst OI. The admission OIs were 
pulmonary TB 28%, extra-pulmonary TB (including 
TB meningitis) 38%, Pneumocystis pneumonia 8%, 
chronic diarrhea (>30 days) 8%, cryptococcal men-
ingitis 6%, Toxoplasma gondii 4% and unknown 8%. 
More than one third (37%) of patients had a low 
BMI of <18.5 kg/m2, and the median admission al-
bumin, creatinine and hemoglobin were respectively 
2.65 g/dl, 1.05 mg/dl and 10.5 g/dl.
ART initiation within 6 months of hospital discharge 
Follow-up at 6 months following hospital discharge 
was available for 45 of the 49 (92%) patients (Table 
2). By this time, 20/45 (45%) patients had initiated 
ART. Among those who initiated ART, the observed 
time from discharge until start of ART was a median 
TB or other acute OI comprise approximately half of 
admissions to the hospital’s medical wards. As part of 
routine in-patient care, HIV and CD4 count testing 
are performed, and at discharge, HIV-infected pa-
tients with a CD4 count of <200 cells/μl are directed 
to enroll as out-patients for ART at the Sinikithemba 
Clinic at McCord Hospital (large vertical site) or at 
one of several other local clinics. 
During the study period from December 2006 un-
til February 2007, HIV-infected, ART-naïve patients 
hospitalized at McCord Hospital with TB or other 
acute OI were approached to enter a pilot project 
which consisted of immediate initiation of ART in a 
step-down center with stavudine, lamivudine and efa-
virenz. Patients were required to pay for the cost of 
additional days of hospitalization (median 14 days, 
interquartile range [IQR] 12–19) associated with the 
immediate ART program. Patients who did not par-
ticipate in this pilot project were prospectively en-
rolled and followed. 
Enrollment criteria
HIV-infected, ART-naïve patients aged ⩾18 years with 
a CD4 cell count of <200 cells/μl (or with World 
Health Organization Stage IV disease) were prospec-
tively enrolled. Patients were excluded if they did not 
indicate both a readiness to initiate ART after dis-
charge and a willingness to be contacted after 6 months 
for follow-up. 
Data collection
Clinical, demographic and laboratory data were col-
lected during admission, and clinical outcomes were 
collected at month 6. Data collected at admission in-
cluded age, sex, education, prior OI history, date of 
HIV diagnosis, use of traditional medicines, body 
mass index (BMI), presence of thrush, CD4 cell count, 
albumin, alanine aminotransferase (ALT), creatinine 
and hemoglobin. Six months after hospital discharge, 
data collected included current medications, date and 
location of current ART clinic (if enrolled), new clini-
cal events (hospitalizations and OI), and vital status 
(obtained from emergency contact, if necessary). At 
that time, patients were also offered a clinic visit at 
McCord Hospital if they had not seen a physician in 
the last month. 
Study design
We conducted an observational, non-randomized 
prospective cohort study. The primary outcomes were 
ART initiation within 6 months of hospital discharge, 
and death within 6 months of hospital discharge.
Statistical analysis
Multivariable logistic regression modeling explored 
the associations between baseline (i.e., pre-hospital dis-
charge) characteristics and ART initiation at 6 months. 
Covariates included in the modeling process were 
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of 83 days (IQR 34.5–119.5). Four participants 
started ART within 1 month of discharge, 2 between 
1 and 2 months, 6 between 2 and 3 months, 3 be-
tween 3 and 4 months, and the remaining 5 between 
4 and 5 months. Pre-discharge covariate associations 
with initiating ART were estimated (Table 3). Use of 
traditional medicine at baseline was associated with 
higher odds of 6-month ART initiation: 78% of pa-
tients using traditional medicine at baseline initiated 
ART by 6 months compared to 36% among patients 
who denied recent use of traditional medicines (P = 
0.04). Furthermore, patients with a higher CD4 cell 
count at baseline of >50 cells/μl had an increased 
odds of initiating ART by 6 months compared to 
Figure  Inclusion of patients in a prospective study of ART uptake and mortality after hospital-
ization with acute OI at McCord Hospital in Durban, South Africa, December 2006–February 
2007. OI = opportunistic infection; ART = antiretroviral therapy.
Table 1  Baseline characteristics of patients at hospital 
admission with acute OI in South Africa
Characteristics (N = 49) n (%)
Median age, years [IQR]     34 [28–40]
Women 24 (49)
Educational level less than secondary school  26 (53)
Median time since initial HIV diagnosis, 
  months [IQR]   2.9 [1.1–3.9]
On an ART waiting list at admission 10 (20)
Alternative medicine use in the last 3 months
  Product sold as ‘immune booster’
 Traditional  medicine
14 (29)
10 (20)
History of prior OI 16 (33)
Opportunistic infection at admission 
 Pulmonary  TB
  Extra-pulmonary TB, including TB meningitis
  Pneumocystis pneumonia
 Chronic  diarrhea*
 Cryptococcal  meningitis









Median weight, kg [IQR] 57.3 [50–62]
Median body mass index, kg/m2 [IQR] 20.3 [17.6–25.4]
Body mass index <18.5 kg/m2† 18  (37)
Median CD4 count, cells/μl [IQR]     42 [14–106]
CD4 cell count category, cells/μl
  ⩽50 
 51–199 





  Albumin, median, g/dl‡
  Creatinine, median, mg/dl
  Hemoglobin, median, g/dl







‡ Fifteen patients did not have a baseline albumin and ALT measurement.
OI = opportunistic infection; IQR = interquartile range; HIV = human im-
munodeﬁ  ciency virus; ART = antiretroviral therapy; TB = tuberculosis; ALT = 
alanine aminotransferase; IU = international unit.
Table 2  Outcomes over 24 weeks following discharge with 
acute OI in KwaZulu-Natal, South Africa
 Patients
     (n = 45)*
Overall incidence of death after discharge, 
    per 100 person/years (95%CI)
  Incidence of death prior to ART initiation 
  Incidence of death following ART initiation
 0.19  (0.11–0.32)
 0.24  (0.14–0.42)
 0.05  (0.0–0.37)
Initiation of ART by 24 weeks
 Initiated  ART,  n (%)
  Observed days from admission to ART 
  initiation,  median  [IQR]† 
20 (46)
83 [34.5–119.5]
Mortality at 24 weeks
  Died before initiating ART, n (%)
  Died after initiating ART, n (%)
  Observed days from discharge to death, 




* Among 49 patients enrolled, four patients were not traceable with the 
contact information provided.
† n = 20.
‡ n = 14.
OI = opportunistic infection; CI = conﬁ  dence interval; ART = antiretroviral 
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those with a CD4 cell count of ⩽50 cells/μl (odds ra-
tio [OR] 3.6, 95%CI 1.04–12.8). This observation 
was partially explained by an increased mortality 
among patients with baseline CD4 count of <50 
cells/μl (10/25 participants with CD4 <50 cells/μl 
later died compared to 4/19 participants with CD4 
⩾50 cells/μl, Fisher’s exact test P = 0.2). In univari-
ate analysis, there was not a signifi  cant association 
identifi  ed between ART initiation and other baseline 
factors including education, date of HIV diagnosis 
(concurrent with hospitalization vs. prior), BMI, 
baseline TB (vs. other OI), ALT, hemoglobin, creati-
nine and albumin.
In multivariate analysis, only recent use of tradi-
tional medicines remained associated with increased 
odds of initiating ART by 6 months (OR 7.2, 95%CI 
1.4–55.1, P = 0.03, Table 3) and CD4 cell count at 
baseline of >50 cells/μl showed a borderline associa-
tion with an increased odds of initiating ART (OR 
1.4, 95%CI 0.9–2.2, P = 0.14).
Mortality within 6 months following discharge 
with tuberculosis or other acute OI
Overall, by 6 months follow-up, 14 (31%) of 45 pa-
tients with follow-up information available had died 
(Table 2). Thirteen of the deaths occurred prior to 
initiation of ART and one occurred 5 days following 
ART initiation. Two deaths occurred within the fi  rst 
month following discharge, 3 between 2 and 3 months, 
5 (including 1 following ART initiation) occurred be-
tween 3 and 4 months, and 2 in each of the intervals 
of 4–5 and 5–6 months following discharge.
This cohort had a total of 20 years of person-time 
follow-up; the overall incidence of death was 0.19 per 
100 person-years (py; 95%CI 0.11–0.32; Table 2). 
The overall incidence of death following initiation of 
ART (with a total of 5.23 years of follow-up available) 
was 0.05 (95%CI 0.01–0.37); the overall incidence 
rate of death before starting ART was 0.24 (95%CI 
0.14–0.42). Before initiating ART, the monthly in-
cidence rate (per 100 py) of death was as follows: 
0.16 (0 to 1 month following discharge), 0.29 (2 to
3 months), 0.54 (3 to 4 months), 0.45 (4 to 5 months) 
and 0.692 (5 to 6 months). 
DISCUSSION
After discharge, patients with TB and other OI enter 
a dangerous clinical trajectory in South Africa that 
includes poor ART access and high early mortality. 








All subjects 45 44
Sex 
 Male 23 39
 Female 22 50 1.6  (0.5–5.1)
Age, years
 0–29  15 47
  ⩾30 30 43 0.9 (0.3–3.0)
Baseline traditional medicine use in 
  past  3  months
 None 36 36
  Traditional medicine use in past 
    2 months 9 78 6.2 (1.1–34.3) 7.2 (1.4–55.1)
Diagnosed with HIV simultaneously 
  with  OI  admission
 No 25 48
 Yes 20 40 0.9  (0.8–1.0)
OIs
  Pulmonary or extra-pulmonary TB 29 45
  OI other than TB 16 44 1.1 (0.3–3.6)
Initial CD4 cell count, cells/μl
 0–49  25 32
  ⩾50  20 60 3.6 (1.04–12.8) 1.4 (0.9–2.2)
Baseline BMI, kg/m2
  ⩾18.5 27 41
  <18.5 18 50 1.5  (0.4–4.8)
Hemoglobin baseline 
  ⩾93 5 4 3
  <9 10 50 1.3 (0.3–5.5)
Baseline albumin, mg/dl*
  ⩾2.5 21 38
  <2.5 13 46 1.4  (0.3–6.5)
* Fifteen patients did not have a baseline albumin measurement.
ART = antiretroviral therapy; OI = opportunistic infection; OR = odds ratio; CI = conﬁ  dence interval; HIV = human 
immunodeﬁ  ciency virus; TB = tuberculosis; BMI = body mass index.ART   uptake   after   TB   in   South   Africa  907
Six months after discharge, more than half of HIV-
i  nfected patients with TB (or other OI) had not initi-
ated ART. During the 6 months after discharge, the 
incidence of death remained high for those not initi-
ating ART. Patients with the most advanced disease 
(CD4 count of <50 cells/μl) appear to have been less 
likely to initiate ART after admission (32% initiated) 
compared to patients with less advanced HIV disease 
(60% initiated). The overall high mortality in this 
c  ohort—and the observation that the incidence of 
mortality prior to starting ART did not fall over time 
—suggests that, in South Africa, mechanisms are ur-
gently needed to expedite ART access for patients 
with advanced HIV disease after OI. This subgroup 
does not appear to have received adequate attention 
in an ART roll-out which has been oriented towards 
the out-patient sector. 
Although acute admission with AIDS-defi  ning ill-
ness continues to be an important initial presentation 
of HIV in southern Africa, in-patients have not been 
a major focus of the ART roll-out. After in-patient ad-
mission in South Africa, patients with HIV infection 
qualifying for ART must queue with out-patients (of-
ten with less advanced disease), and participate in the 
same pre-ART readiness-assessment process. As this 
study demonstrates, the current model may impose 
signifi  cant barriers for this vulnerable patient group. 
To improve continuity of care after in-patient ad-
mission, new treatment models are required for HIV-
infected patients presenting to in-patient wards. These 
could include the use of an in-patient ART initiation 
model or out-patient ‘fast-track’ mechanisms that could 
triage patients with TB or other OI to out-patient 
ART initiation within weeks, and not months, with 
less stringent preparation and training requirements.
A signifi  cant association was found between the 
baseline use of traditional medicine and an increased 
odds of ART initiation by 6 months. The use of tradi-
tional medicines may be a marker for health-seeking 
behavior. 
The study has important limitations. The small 
sample size makes it diffi  cult to model multiple base-
line factors in a single model to predict the primary 
outcome of ART initiation after OI, and the study 
therefore had power to detect only large associations 
with this outcome. The fi  ndings presented in this re-
port cannot be generalized to all settings in South 
Africa. The site of the study (McCord Hospital) in-
cludes a hospital and an ART clinic with adequate 
human resources. It is likely that the outcomes de-
scribed among HIV-infected patients with TB and 
other acute OI in this report, compared to the public 
hospital sector in KwaZulu-Natal, represent a best-
case scenario. A potential source of bias relates to the 
inclusion criteria for this study: participants were pa-
tients with acute OI who were eligible but elected not 
to participate in an ongoing in-patient ART initiation 
program that required an additional 2 weeks of hos-
pitalization with associated costs.
Despite an initial intention by all patients to com-
mence out-patient ART, less than half had succeeded 
by 6 months. To meet the needs of this patient group, 
creative and pragmatic new care models are needed. 
Researchers must initiate high quality patient-oriented 
research to meet this gap and urgently communicate 
results from ongoing programs focusing on this vul-
nerable patient group.
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RÉSUMÉ
OBJECTIFS :    On a mené une étude prospective de co-
horte parmi les patients hospitalisés pour tuberculose 
(TB) ou d’autres infections opportunistes (OI) et infec-
tés par le virus de l’immunodéfi  cience humaine (VIH) en 
Afrique du Sud pour estimer le recours ultérieur à un 
traitement antirétroviral (ART) et la survie.
MÉTHODES :    On a exploré par les modèles de régres-
sion logistique les associations entre les caractéristiques 
du début et la mise en route de l’ART ainsi que l’in-
cidence de décès ajustée pour l’ART au cours d’un suivi 
de 6 mois.
RÉSULTATS :    Parmi les 49 participants enrôlés, le d  é-
compte médian des cellules CD4 à la sortie de l’hôpital 
a été de 42 cellules/μl et les OI les plus couramment 908  The   International   Journal   of   Tuberculosis   and   Lung   Disease
observées ont été la TB (76%), la pneumonie à Pneu-
mocystis (8%), la diarrhée chronique (8%), la méningite 
à cryptocoques (6%) et la toxoplasmose (Toxoplasma 
gondii ; 4%). A 6 mois, 20 sujets seulement avaient 
commencé l’ART (45%) et quatre (8%) ont été perdus 
de vue. La mise en route de l’ART est en association in-
dépendante avec le recours antérieur à la médecine tra-
ditionnelle (OR 7,2 ; IC95% 1,4–55,1), ainsi qu’avec 
une infection VIH moins avancée (décompte de CD4 au 
départ OR 1,4 ; IC95% 0,9–2,2 par augmentation de 
50 cellules/μl). Au total, il y a eu 14 décès (31%) avant 
la mise en route de l’ART et l’incidence mensuelle de 
décès n’a pas diminué au cours du suivi de 6 mois.
CONCLUSION :    La mortalité élevée observée au cours 
des 6 mois suivant l’hospitalisation pour TB ou autre OI 
aiguë plaide en faveur de la nécessité de mécanismes 
d’accélération de la mise en route de l’ART chez les pa-
tients atteints d’une maladie entrant dans la défi  nition 
du syndrome d’immunodéfi  cience acquise.
RESUMEN
OBJETIVOS:    Se llevó a cabo un estudio prospectivo de 
cohortes en pacientes hospitalizados con infección por 
el virus de la inmunodefi  ciencia humana (VIH) y tuber-
culosis (TB) u otra infección oportunista (OI) en Sud-
áfrica, con el fi  n de calcular la proporción de pacientes 
que aceptan luego el tratamiento antirretrovírico (ART) 
y su supervivencia. 
MÉTODOS:    Mediante un modelo de regresión logística 
se analizó la asociación entre las características iniciales 
de los pacientes, el comienzo del ART y la mortalidad 
ajustada a la exposición a este tratamiento, en un segui-
miento de 6 meses de duración.
RESULTADOS:    En los 49 participantes del estudio, la 
mediana del recuento de células CD4 en el momento del 
alta hospitalaria fue 42 células/μl y las infecciones opor-
tunistas más frecuentes fueron la TB (76%), la neu-
monía por Pneumocystis (8%), la diarrea crónica (8%), 
la meningitis por criptococo (6%) y el parasitismo por 
Toxoplasma gondii (4%). A los 6 meses, solo 20 pacien-
tes (45%) habían iniciado el ART y cuatro (8%) se per-
dieron durante el seguimiento. La aceptación de este 
tratamiento se asoció en forma independiente con una 
experiencia previa con la medicina tradicional (OR 7,2; 
IC95% 1,4–55,1) y con una infección por el VIH menos 
avanzada (recuento inicial de CD4, por cada 50 células/
μl un aumento del OR de 1,4; IC95% 0,9–2,2). Catorce 
pacientes (31%) fallecieron antes de comenzar el ART; 
la mortalidad mensual no disminuyó durante el inter-
valo de 6 meses. 
CONCLUSIÓN:    La alta mortalidad observada en los 
primeros 6 meses posteriores a una hospitalización por 
TB u otra OI es un argumento en favor de la introduc-
ción de un mecanismo que acelere la administración del 
ART en los pacientes que presentan una enfermedad 
que defi  ne la aparición del síndrome de inmunodefi  cien-
cia adquirida.